What is the level of liabilities of MacroGenics this year?
MacroGenics has a debt balance of 145.8 M USD this year.
MacroGenics Liabilities 2024
MacroGenics Liabilities
145.8 M USD
Ticker
MGNX
ISIN
US5560991094
WKN
A1W6ND
In 2024, MacroGenics's total liabilities amounted to 145.8 M USD, a 5.27% difference from the 138.5 M USD total liabilities in the previous year.
MacroGenics Aktienanalyse
What does MacroGenics do?
MacroGenics Inc is a biotechnology company that was founded in 2000 and is headquartered in Rockville, Maryland, USA. The company specializes in the research, development, and commercialization of therapeutic antibodies used in the treatment of cancer and autoimmune diseases. MacroGenics' business model is based on the production of different antibodies that primarily target various cell types and thereby elicit a targeted response. The company relies on a balanced approach to research and development to preferentially identify cellular markers that are characteristic of certain diseases, allowing for the identification of specific target molecules for antibody development. These innovative therapies lead to an improvement in the quality of life for patients by curing or at least managing severe diseases. Over the years, MacroGenics has built several divisions, including: Antibody platform technologies MacroGenics utilizes its proprietary platform technology for phage display and antibody manufacturing (Digitalis), as well as for the discovery of target molecules responsible for specific diseases. These technologies are used to identify new therapeutic antibody candidates and support the entire antibody development process. Cancer research and development MacroGenics is a pioneer in the development of innovative cancer therapies. One of the key products in this area is the antibody-based cancer drug Margetuximab, used for the treatment of metastatic breast cancer. Another promising drug in clinical phases is MGD019, which is highly effective for tumor treatment in the solid area. Autoimmune research and development MacroGenics is a leading developer of Neuromyelitis Optica Spectrum Disorder (NMOSD), which leads to recurring inflammation of the central nervous system. Additional products in the pipeline are being developed for the treatment of autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, as there is still a wide range of needs in this field. Polyclonals and biosimilars This area includes the production of antibody polypeptides and biosimilar drugs. Antibody polypeptides can be used to treat infectious diseases or diagnose diseases. Biosimilar drugs are biological drugs that have similar active ingredients to other already approved drugs and are approved by the US Food and Drug Administration (FDA). These drugs are also known as generic replicas. MacroGenics' products have proven to be safe and effective in clinical trials. The company has established an extensive network of collaborations to market and distribute its products. Partners include major pharmaceutical companies such as Pfizer, Servier, and Janssen Biotech. Overall, MacroGenics has over 20 product pipelines in various stages of development and is constantly working to expand its product pipelines. The company employs over 400 employees and aims to revolutionize the treatment of severe and life-threatening diseases. In conclusion, MacroGenics Inc is an innovative biotechnology company that has developed and designed a variety of products for the treatment of cancer and autoimmune diseases. The company has a wide range of proprietary platform technologies and is constantly striving to expand its product pipelines. We expect the company to continue growing in the coming years and harness its innovative power to further benefit patients. MacroGenics ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing MacroGenics's Liabilities
MacroGenics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating MacroGenics's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing MacroGenics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
MacroGenics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in MacroGenics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about MacroGenics stock
What were the liabilities of MacroGenics compared to the previous year?
The liabilities of MacroGenics have increased by 5.27% increased compared to the previous year.
What are the consequences of high debt for investors of MacroGenics?
High liabilities can pose a risk for investors of MacroGenics, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in MacroGenics?
Low liabilities mean that MacroGenics has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of MacroGenics affect the company?
An increase in liabilities of MacroGenics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of MacroGenics affect the company?
A decrease in the liabilities of MacroGenics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of MacroGenics?
Some factors that can influence the liabilities of MacroGenics include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of MacroGenics so important for investors?
The liabilities of MacroGenics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can MacroGenics take to modify the liabilities?
To change its liabilities, MacroGenics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does MacroGenics pay?
Over the past 12 months, MacroGenics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, MacroGenics is expected to pay a dividend of 0 USD.
What is the dividend yield of MacroGenics?
The current dividend yield of MacroGenics is .
When does MacroGenics pay dividends?
MacroGenics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of MacroGenics?
MacroGenics paid dividends every year for the past 0 years.
What is the dividend of MacroGenics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is MacroGenics located?
MacroGenics is assigned to the 'Health' sector.
Wann musste ich die Aktien von MacroGenics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of MacroGenics from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.
When did MacroGenics pay the last dividend?
The last dividend was paid out on 9/13/2024.
What was the dividend of MacroGenics in the year 2023?
In the year 2023, MacroGenics distributed 0 USD as dividends.
In which currency does MacroGenics pay out the dividend?
The dividends of MacroGenics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The MacroGenics stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von MacroGenics
Our stock analysis for MacroGenics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MacroGenics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
